Higashi Study Highlights & Related Information
A randomized, double-blind, parallel-group, placebo-controlled, multicenter study, reviewed and confirmed by the FDA’s New Drug Application process, means this is an OTC topical analgesic that has the clinical proof and approval few have.
Strong Clinical Trial Results
40% Additional relief experienced with Salonpas® vs Placebo
58% Study patients rating satisfaction from Salonpas® as good/very good/excellent
From a randomized, double-blind, parallel-group, placebo-controlled, multicenter study1
Passed Rigorous FDA Review
<10% Less than 10% of OTC drug products have an NDA or have even been reviewed by the FDA
Salonpas® is the first OTC topical pain treatment to earn an NDA
The FDA’s New Drug Application (NDA) process is a rigorous process that every prescription medicine since 1938 has passed through.
Salonpas® is the first OTC labeled to treat both mild and moderate pain
Near-Zero Side Effects
.001% Rate of adverse events to Patch sales2
Long-Lasting, Controlled Dose
Treatment works locally, significant pain relief can start within 1 hour and lasts for up to 12 hours, with very little medicine traveling throughout the bloodstream. Some individuals may not experience pain relief until several hours after applying the patch.